Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients
Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy i...
Gespeichert in:
Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2017-09, Vol.5 (5), p.1264-1271 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1271 |
---|---|
container_issue | 5 |
container_start_page | 1264 |
container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
container_volume | 5 |
creator | Vos, Byrthe J.P.R., MD, PhD van Anrooij, Bjorn, BSc van Doormaal, Jasper J., MD, PhD Dubois, Anthony E.J., MD, PhD Oude Elberink, Joanne N.G., MD, PhD |
description | Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L. |
doi_str_mv | 10.1016/j.jaip.2017.03.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899116516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219817301903</els_id><sourcerecordid>1899116516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAUjBCIVqV_gAOyxIVLgj8SfyCEtKooFBUV0XLgZLn2CzibjVPbS9l_j6NtQeoBX2yNZ0bvvXlV9ZzghmDCXw_NYPzcUExEg1mDiXpUHVJKWE0L9vj-TZQ8qI5TGnA5kgjc4qfVAZWtUkLIw-r21GQzotVk5p-70fz2CeWAvsM4hlv0ydg1ZHSZ_fQjIT-hzyblYHc5JJ_eoIs5-zAl1IeIzhxM2ffemgVDZnLoKoLJmwKj0KNVrr_6tEZfyn-B0rPqSW_GBMd391H17fT91cnH-vziw9nJ6ry2rWS5Nsw4I6XqsO0xB9VzIB1AJ2grqJJUcutA9gY65zinlPOWO0mZIHDdgjHsqHq1951juNlCynrjky3tmQnCNmkilSKEd4QX6ssH1CFs41Sq00QxIbhqeVdYdM-yMaQUoddz9BsTd5pgvSSjB70ko5dkNGa6JFNEL-6st9cbcH8l9zkUwts9AcosfnmIOtkyJwvOR7BZu-D_7__ugdyOfiphjGvYQfrXh05UY3257MayGkSwIseM_QEzV7Qm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937769465</pqid></control><display><type>article</type><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</creator><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><description>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2017.03.019</identifier><identifier>PMID: 28499778</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Accuracy ; Adult ; Adults ; Allergens - immunology ; Allergies ; Allergy and Immunology ; Anaphylaxis ; Anaphylaxis - diagnosis ; Anaphylaxis - epidemiology ; Anaphylaxis - therapy ; Animal bites ; Animals ; Bees ; Desensitization, Immunologic - methods ; Epidemiology ; Epinephrine - therapeutic use ; Fatal Outcome ; Female ; Health risk assessment ; Humans ; Hymenoptera ; Immunoglobulin E ; Immunoglobulin E - blood ; Immunotherapy ; Indolent systemic mastocytosis ; Insect Bites and Stings - diagnosis ; Insect Bites and Stings - epidemiology ; Internal Medicine ; Male ; Mastocytosis ; Mastocytosis, Systemic - diagnosis ; Mastocytosis, Systemic - epidemiology ; Mastocytosis, Systemic - therapy ; Middle Aged ; Patients ; Risk ; Sensitivity and Specificity ; Sensitization ; Specific IgE ; Stings ; Tryptases - blood ; Urticaria Pigmentosa ; Venom ; Ves v 5 ; Wasp Venoms - immunology ; Wasps ; Yellow jacket</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-09, Vol.5 (5), p.1264-1271</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2017 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</citedby><cites>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28499778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD</creatorcontrib><creatorcontrib>van Anrooij, Bjorn, BSc</creatorcontrib><creatorcontrib>van Doormaal, Jasper J., MD, PhD</creatorcontrib><creatorcontrib>Dubois, Anthony E.J., MD, PhD</creatorcontrib><creatorcontrib>Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</description><subject>Accuracy</subject><subject>Adult</subject><subject>Adults</subject><subject>Allergens - immunology</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Anaphylaxis</subject><subject>Anaphylaxis - diagnosis</subject><subject>Anaphylaxis - epidemiology</subject><subject>Anaphylaxis - therapy</subject><subject>Animal bites</subject><subject>Animals</subject><subject>Bees</subject><subject>Desensitization, Immunologic - methods</subject><subject>Epidemiology</subject><subject>Epinephrine - therapeutic use</subject><subject>Fatal Outcome</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hymenoptera</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin E - blood</subject><subject>Immunotherapy</subject><subject>Indolent systemic mastocytosis</subject><subject>Insect Bites and Stings - diagnosis</subject><subject>Insect Bites and Stings - epidemiology</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Mastocytosis</subject><subject>Mastocytosis, Systemic - diagnosis</subject><subject>Mastocytosis, Systemic - epidemiology</subject><subject>Mastocytosis, Systemic - therapy</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Risk</subject><subject>Sensitivity and Specificity</subject><subject>Sensitization</subject><subject>Specific IgE</subject><subject>Stings</subject><subject>Tryptases - blood</subject><subject>Urticaria Pigmentosa</subject><subject>Venom</subject><subject>Ves v 5</subject><subject>Wasp Venoms - immunology</subject><subject>Wasps</subject><subject>Yellow jacket</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk1v1DAUjBCIVqV_gAOyxIVLgj8SfyCEtKooFBUV0XLgZLn2CzibjVPbS9l_j6NtQeoBX2yNZ0bvvXlV9ZzghmDCXw_NYPzcUExEg1mDiXpUHVJKWE0L9vj-TZQ8qI5TGnA5kgjc4qfVAZWtUkLIw-r21GQzotVk5p-70fz2CeWAvsM4hlv0ydg1ZHSZ_fQjIT-hzyblYHc5JJ_eoIs5-zAl1IeIzhxM2ffemgVDZnLoKoLJmwKj0KNVrr_6tEZfyn-B0rPqSW_GBMd391H17fT91cnH-vziw9nJ6ry2rWS5Nsw4I6XqsO0xB9VzIB1AJ2grqJJUcutA9gY65zinlPOWO0mZIHDdgjHsqHq1951juNlCynrjky3tmQnCNmkilSKEd4QX6ssH1CFs41Sq00QxIbhqeVdYdM-yMaQUoddz9BsTd5pgvSSjB70ko5dkNGa6JFNEL-6st9cbcH8l9zkUwts9AcosfnmIOtkyJwvOR7BZu-D_7__ugdyOfiphjGvYQfrXh05UY3257MayGkSwIseM_QEzV7Qm</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Vos, Byrthe J.P.R., MD, PhD</creator><creator>van Anrooij, Bjorn, BSc</creator><creator>van Doormaal, Jasper J., MD, PhD</creator><creator>Dubois, Anthony E.J., MD, PhD</creator><creator>Oude Elberink, Joanne N.G., MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><author>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Accuracy</topic><topic>Adult</topic><topic>Adults</topic><topic>Allergens - immunology</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Anaphylaxis</topic><topic>Anaphylaxis - diagnosis</topic><topic>Anaphylaxis - epidemiology</topic><topic>Anaphylaxis - therapy</topic><topic>Animal bites</topic><topic>Animals</topic><topic>Bees</topic><topic>Desensitization, Immunologic - methods</topic><topic>Epidemiology</topic><topic>Epinephrine - therapeutic use</topic><topic>Fatal Outcome</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hymenoptera</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin E - blood</topic><topic>Immunotherapy</topic><topic>Indolent systemic mastocytosis</topic><topic>Insect Bites and Stings - diagnosis</topic><topic>Insect Bites and Stings - epidemiology</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Mastocytosis</topic><topic>Mastocytosis, Systemic - diagnosis</topic><topic>Mastocytosis, Systemic - epidemiology</topic><topic>Mastocytosis, Systemic - therapy</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Risk</topic><topic>Sensitivity and Specificity</topic><topic>Sensitization</topic><topic>Specific IgE</topic><topic>Stings</topic><topic>Tryptases - blood</topic><topic>Urticaria Pigmentosa</topic><topic>Venom</topic><topic>Ves v 5</topic><topic>Wasp Venoms - immunology</topic><topic>Wasps</topic><topic>Yellow jacket</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD</creatorcontrib><creatorcontrib>van Anrooij, Bjorn, BSc</creatorcontrib><creatorcontrib>van Doormaal, Jasper J., MD, PhD</creatorcontrib><creatorcontrib>Dubois, Anthony E.J., MD, PhD</creatorcontrib><creatorcontrib>Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vos, Byrthe J.P.R., MD, PhD</au><au>van Anrooij, Bjorn, BSc</au><au>van Doormaal, Jasper J., MD, PhD</au><au>Dubois, Anthony E.J., MD, PhD</au><au>Oude Elberink, Joanne N.G., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>5</volume><issue>5</issue><spage>1264</spage><epage>1271</epage><pages>1264-1271</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28499778</pmid><doi>10.1016/j.jaip.2017.03.019</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2213-2198 |
ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-09, Vol.5 (5), p.1264-1271 |
issn | 2213-2198 2213-2201 |
language | eng |
recordid | cdi_proquest_miscellaneous_1899116516 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Accuracy Adult Adults Allergens - immunology Allergies Allergy and Immunology Anaphylaxis Anaphylaxis - diagnosis Anaphylaxis - epidemiology Anaphylaxis - therapy Animal bites Animals Bees Desensitization, Immunologic - methods Epidemiology Epinephrine - therapeutic use Fatal Outcome Female Health risk assessment Humans Hymenoptera Immunoglobulin E Immunoglobulin E - blood Immunotherapy Indolent systemic mastocytosis Insect Bites and Stings - diagnosis Insect Bites and Stings - epidemiology Internal Medicine Male Mastocytosis Mastocytosis, Systemic - diagnosis Mastocytosis, Systemic - epidemiology Mastocytosis, Systemic - therapy Middle Aged Patients Risk Sensitivity and Specificity Sensitization Specific IgE Stings Tryptases - blood Urticaria Pigmentosa Venom Ves v 5 Wasp Venoms - immunology Wasps Yellow jacket |
title | Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatal%20Anaphylaxis%20to%20Yellow%20Jacket%20Stings%20in%20Mastocytosis:%20Options%20for%20Identification%20and%20Treatment%20of%20At-Risk%20Patients&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Vos,%20Byrthe%20J.P.R.,%20MD,%20PhD&rft.date=2017-09-01&rft.volume=5&rft.issue=5&rft.spage=1264&rft.epage=1271&rft.pages=1264-1271&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2017.03.019&rft_dat=%3Cproquest_cross%3E1899116516%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1937769465&rft_id=info:pmid/28499778&rft_els_id=S2213219817301903&rfr_iscdi=true |